| pubmed-article:15328518 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15328518 | lifeskim:mentions | umls-concept:C0011065 | lld:lifeskim |
| pubmed-article:15328518 | lifeskim:mentions | umls-concept:C0017636 | lld:lifeskim |
| pubmed-article:15328518 | lifeskim:mentions | umls-concept:C0178539 | lld:lifeskim |
| pubmed-article:15328518 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:15328518 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:15328518 | lifeskim:mentions | umls-concept:C0338204 | lld:lifeskim |
| pubmed-article:15328518 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15328518 | pubmed:dateCreated | 2004-10-11 | lld:pubmed |
| pubmed-article:15328518 | pubmed:abstractText | Glioblastoma multiforme (GBM) remains the most devastating primary tumour in neuro-oncology. Targeting of the human epithelial receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumours. Human epithelial receptor type 2/neu is a transmembrane tyrosine/kinase receptor that appears to be important for the regulation of cancer growth. Human epithelial receptor type 2/neu is not expressed in the adult central nervous system, but its expression increases with the degree of astrocytoma anaplasia. The specificity of HER2/neu for tumoral astrocytomas leads us to study in vitro treatment of GBM with anti-HER2/neu antibody. We used human GBM cell lines expressing HER2/neu (A172 express HER2/neu more than U251MG) or not (U87MG) and monoclonal humanised antibody against HER2/neu (Herceptin). Human epithelial receptor type 2/neu expression was measured by immunohistochemistry and flow cytometry. Direct antibody effect, complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity were evaluated by different cytometric assays. We have shown, for the first time, the ability of anti-HER2/neu antibodies to induce apoptosis and cellular-dependent cytotoxicity of HER2/neu-expressing GBM cell lines. The results decreased from A172 to U251 and were negative for U87MG, in accordance with the decreasing density of HER2/neu receptors. | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15328518 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15328518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15328518 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15328518 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:15328518 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:15328518 | pubmed:author | pubmed-author:LagardeNN | lld:pubmed |
| pubmed-article:15328518 | pubmed:author | pubmed-author:BerthouCC | lld:pubmed |
| pubmed-article:15328518 | pubmed:author | pubmed-author:RYANB KBK | lld:pubmed |
| pubmed-article:15328518 | pubmed:author | pubmed-author:BulaJJ | lld:pubmed |
| pubmed-article:15328518 | pubmed:author | pubmed-author:BordronAA | lld:pubmed |
| pubmed-article:15328518 | pubmed:author | pubmed-author:Quintin-RouéI... | lld:pubmed |
| pubmed-article:15328518 | pubmed:author | pubmed-author:LoiselSS | lld:pubmed |
| pubmed-article:15328518 | pubmed:author | pubmed-author:MineoJ-FJF | lld:pubmed |
| pubmed-article:15328518 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15328518 | pubmed:day | 13 | lld:pubmed |
| pubmed-article:15328518 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:15328518 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15328518 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15328518 | pubmed:pagination | 1195-9 | lld:pubmed |
| pubmed-article:15328518 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:15328518 | pubmed:meshHeading | pubmed-meshheading:15328518... | lld:pubmed |
| pubmed-article:15328518 | pubmed:meshHeading | pubmed-meshheading:15328518... | lld:pubmed |
| pubmed-article:15328518 | pubmed:meshHeading | pubmed-meshheading:15328518... | lld:pubmed |
| pubmed-article:15328518 | pubmed:meshHeading | pubmed-meshheading:15328518... | lld:pubmed |
| pubmed-article:15328518 | pubmed:meshHeading | pubmed-meshheading:15328518... | lld:pubmed |
| pubmed-article:15328518 | pubmed:meshHeading | pubmed-meshheading:15328518... | lld:pubmed |
| pubmed-article:15328518 | pubmed:meshHeading | pubmed-meshheading:15328518... | lld:pubmed |
| pubmed-article:15328518 | pubmed:meshHeading | pubmed-meshheading:15328518... | lld:pubmed |
| pubmed-article:15328518 | pubmed:meshHeading | pubmed-meshheading:15328518... | lld:pubmed |
| pubmed-article:15328518 | pubmed:meshHeading | pubmed-meshheading:15328518... | lld:pubmed |
| pubmed-article:15328518 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15328518 | pubmed:articleTitle | Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas. | lld:pubmed |
| pubmed-article:15328518 | pubmed:affiliation | Department of Neurosurgery, University Medical School Hospital of Brest, BP 824, F29609 Brest Cedex, France. jfmineo@hotmail.com | lld:pubmed |
| pubmed-article:15328518 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15328518 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15328518 | lld:pubmed |
